452 related articles for article (PubMed ID: 21455605)
21. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
Hiwase DK; White DL; Powell JA; Saunders VA; Zrim SA; Frede AK; Guthridge MA; Lopez AF; D'Andrea RJ; To LB; Melo JV; Kumar S; Hughes TP
Leukemia; 2010 Apr; 24(4):771-8. PubMed ID: 20130598
[TBL] [Abstract][Full Text] [Related]
22. Methyl-β-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and, combined with imatinib, produces a synergistic downregulation of ERK/SPK1 signaling.
Yan J; Li QF; Wang LS; Wang H; Xiao FJ; Yang YF; Wu CT
Anticancer Drugs; 2012 Jan; 23(1):22-31. PubMed ID: 21857502
[TBL] [Abstract][Full Text] [Related]
23. Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression.
Dai L; Trillo-Tinoco J; Bai A; Chen Y; Bielawski J; Del Valle L; Smith CD; Ochoa AC; Qin Z; Parsons C
Oncotarget; 2015 Sep; 6(27):24246-60. PubMed ID: 26327294
[TBL] [Abstract][Full Text] [Related]
24. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells.
Bonhoure E; Lauret A; Barnes DJ; Martin C; Malavaud B; Kohama T; Melo JV; Cuvillier O
Leukemia; 2008 May; 22(5):971-9. PubMed ID: 18401414
[TBL] [Abstract][Full Text] [Related]
25. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia.
Itoh M; Kitano T; Watanabe M; Kondo T; Yabu T; Taguchi Y; Iwai K; Tashima M; Uchiyama T; Okazaki T
Clin Cancer Res; 2003 Jan; 9(1):415-23. PubMed ID: 12538495
[TBL] [Abstract][Full Text] [Related]
26. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
27. Management of Bcr-Abl-positive leukemias with dasatinib.
Hochhaus A
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
[TBL] [Abstract][Full Text] [Related]
28. Sphingolipids and response to chemotherapy.
Dimanche-Boitrel MT; Rebillard A
Handb Exp Pharmacol; 2013; (216):73-91. PubMed ID: 23563652
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Li QF; Yan J; Zhang K; Yang YF; Xiao FJ; Wu CT; Wang H; Wang LS
Biochem Biophys Res Commun; 2011 Feb; 405(1):31-6. PubMed ID: 21195056
[TBL] [Abstract][Full Text] [Related]
30. Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes.
Ersöz NŞ; Adan A
Med Oncol; 2022 Jan; 39(3):35. PubMed ID: 35059910
[TBL] [Abstract][Full Text] [Related]
31. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.
Chandramohan Reddy T; Bharat Reddy D; Aparna A; Arunasree KM; Gupta G; Achari C; Reddy GV; Lakshmipathi V; Subramanyam A; Reddanna P
Toxicol In Vitro; 2012 Apr; 26(3):396-405. PubMed ID: 22245431
[TBL] [Abstract][Full Text] [Related]
32. Apoptotic effects of resveratrol, a grape polyphenol, on imatinib-sensitive and resistant K562 chronic myeloid leukemia cells.
Can G; Cakir Z; Kartal M; Gunduz U; Baran Y
Anticancer Res; 2012 Jul; 32(7):2673-8. PubMed ID: 22753725
[TBL] [Abstract][Full Text] [Related]
33. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1.
Bonhoure E; Pchejetski D; Aouali N; Morjani H; Levade T; Kohama T; Cuvillier O
Leukemia; 2006 Jan; 20(1):95-102. PubMed ID: 16281067
[TBL] [Abstract][Full Text] [Related]
34. Resveratrol induces apoptosis of leukemia cell line K562 by modulation of sphingosine kinase-1 pathway.
Tian H; Yu Z
Int J Clin Exp Pathol; 2015; 8(3):2755-62. PubMed ID: 26045781
[TBL] [Abstract][Full Text] [Related]
35. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
Baran Y; Oztekin C; Bassoy EY
Cancer Invest; 2010 Jul; 28(6):623-8. PubMed ID: 20307198
[TBL] [Abstract][Full Text] [Related]
36. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
37. The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: oxidative stress and the seesaw of cell survival and death.
Van Brocklyn JR; Williams JB
Comp Biochem Physiol B Biochem Mol Biol; 2012 Sep; 163(1):26-36. PubMed ID: 22613819
[TBL] [Abstract][Full Text] [Related]
38. Imatinib-induced apoptosis: a possible link to topoisomerase enzyme inhibition.
Baran Y; Zencir S; Cakir Z; Ozturk E; Topcu Z
J Clin Pharm Ther; 2011 Dec; 36(6):673-9. PubMed ID: 21105880
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
40. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Shah NP; Kasap C; Weier C; Balbas M; Nicoll JM; Bleickardt E; Nicaise C; Sawyers CL
Cancer Cell; 2008 Dec; 14(6):485-93. PubMed ID: 19061839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
